In murine glioma, HEV formation was induced by treatment with a vascular targeting peptide delivering LIGHT/TNFSF14 or when using a lymphotoxin β receptor agonist, and was further enhanced by anti-VEGF and ICI therapy (67, 68). Here, TNFSF14 is linked to central nervous system cancer.